Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant
Status:
Suspended
Trial end date:
2022-02-15
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the best dose and side effects of ibrutinib when given together
with lenalidomide and dexamethasone and how well they work in treating patients with multiple
myeloma that are not eligible for transplant. Ibrutinib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving ibrutinib, lenalidomide, and dexamethasone may work better in treating
patients with multiple myeloma.